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Abstract 
THE STUDY OF THE EFFECT OF DRUGS OF ABUSE ON PROTEIN KINASE A 
ACTIVITY IN MOUSE BRAIN AND SPINAL CORD. 
By George D. Dalton, Ph.D. 
A dissertation submitted in partial fulfillment of the requirements for the degree of 
Doctor of Philosophy at Virginia Commonwealth University. 
Virginia Commonwealth University, 2005. 
Dr. William L. Dewey, Professor, Department of Pharmacology & Toxicology 
Morphine and A9-THC are drugs that produce analgesia and rewarding effects. However, 
chronic treatment with morphine and a9-THC produces problematic side-effects 
including tolerance and physical dependence. The cellular mechanisms underlying opioid 
and cannabinoid antinociceptive tolerance have been studied for years. Research has 
demonstrated that the expression of morphine and A~-THC antinociceptive tolerance may 
be mediated through intracellular signaling pathways, such as the adenylyl cyclase 
/Protein Kinase A (PKA) cascade. The present study investigated the role of PKA in the 
expression of morphine and a9-THC antinociceptive tolerance. Male Swiss Webster mice 
were treated chronically with morphine or A~-THC and the warm-water tail-flick test was 
used to assess antinociception. These studies revealed that the level and the duration of 
morphine antinociceptive tolerance both influenced whether 
PKA activity was increased in mouse brain and spinal cord. Cytosolic PKA activity was 
increased in the thalamus of 3-day morphine-tolerant mice expressing a 45-fold level of 
tolerance, but not in mice that expressed a 10-fold level of tolerance. In addition, 
cytosolic PKA activity was increased in the lumbar spinal cord (LSC) of 15-day 
morphine-tolerant mice. However, chronic treatment with A9-THC had no effect on 
neuronal PKA activity even in mice that expressed a high level of antinociceptive 
tolerance. The absence of an effect of chronic treatment with A9-THC on neuronal PKA 
activity was supported by the development of a positive control in which the PKA 
activator Sp-8-Br-CAMPS was administered intracerebroventricularly (i.c.v.) and 
intrathecally (i.t.) in drug-naYve mice and increases in PKA activity were observed in 
several brain regions and LSC. Finally, the i.c.v. injection of two peptide fragments of 
native Protein Kinase A inhibitor (PKI) peptide, PKI-(6-22)-amide and PKI-(Myr- 14-22)- 
amide, significantly reversed antinociceptive tolerance in mice treated chronically with 
morphine. PKI-(6-22)-amide (i.c.v.) also inhibited PKA activity in brain regions 
(thalamus, periaqueductal gray (PAG), and medulla) and LSC, which studies have shown 
play a role in morphine-induced analgesia. Moreover, PKI-(6-22)-amide reduced the 
increase in PKA activity in thalamus and LSC observed with chronic morphine treatment. 
Overall, these studies provide evidence that PKA plays a role in morphine tolerance, but 
not A~-THC tolerance at the doses and times tested. 








































































































































